Gut microbiota: a potential therapeutic target for hyperuricemia and gout.
- 2026
- Bioscience of microbiota, food and health 45(2)
- Jiahui Tang
- Yaxi Liu
- Nianwei Wu
- Jie Lu
- Yuwei Zhang
- Nanwei Tong
- Qingguo Lü
- PubMed: 42006120
- DOI: 10.12938/bmfh.2025-042
Study Design
- Type
- Review
The prevalence of hyperuricemia (HUA) and gout has increased in recent decades. Current therapeutic approaches for HUA/gout are often limited by potential risks, necessitating the exploration of safer and more effective treatment options. Emerging evidence highlights the gut microbiota as a pivotal regulator of uric acid (UA) homeostasis. This review synthesizes current advances in microbiota-targeted interventions for HUA/gout, focusing on mechanistic insights and translational potential. We aim to provide a roadmap for optimizing microbiota-based therapies in HUA/gout management by bridging mechanistic discoveries with clinical translation. Gut microbiota can mitigate HUA/gout through several mechanisms, including regulating UA and purine metabolism, alleviating inflammation and modulating immune response, and enhancing the integrity of the intestinal barrier. Therapeutic strategies targeting gut microbiota include probiotics, prebiotics, traditional Chinese medicine, and fecal microbiota transplantation, which offer multi-target and multi-pathway benefits. While these microbiota-targeted therapies offer advantages over conventional drugs, several challenges remain. Future research should prioritize mechanistic elucidation, personalized microbiota modulation, and large-scale trials to optimize therapeutic paradigms for HUA/gout.